Production (Stage)
Voyager Therapeutics, Inc.
VYGR
$2.92
-$0.07-2.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,682.29% | -149.12% | -50.52% | -90.58% | -103.08% |
| Total Depreciation and Amortization | -0.28% | 6.53% | 28.30% | 12.27% | 2.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.47% | 44.83% | 11.37% | -4.97% | 5.29% |
| Change in Net Operating Assets | -1,285.37% | 150.79% | -373.18% | -155.88% | 110.87% |
| Cash from Operations | -953.38% | -119.65% | -127.44% | -118.69% | -82.88% |
| Capital Expenditure | 58.31% | -8.14% | -20.01% | -58.53% | -65.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 117.97% | 34.00% | 75.69% | -722.99% | -921.30% |
| Cash from Investing | 116.81% | 33.03% | 73.56% | -782.29% | -1,028.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.92% | 238.88% | 240.40% | 244.60% | 255.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.92% | 238.88% | 240.40% | 244.60% | 255.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.85% | 112.79% | 254.02% | -200.51% | -190.97% |